ArticlePediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2026
MicroRNA clustering in pediatric asthma reveals differential corticosteroid responsiveness.
Article in Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MicroRNA clustering in pediatric asthma reveals differential corticosteroid responsiveness.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAsthma is a heterogeneous disease with variable treatment responses. miRNAs play a critical role in asthma pathogenesis and may serve as biomarkers for distinct asthma endotypes. We tried to identify possible molecular asthma clusters based on miRNA expression profiles in pediatric patients from the Childhood Asthma Management Program (CAMP) cohort.
methodsWe performed miRNA profiling and k-means clustering on 462 CAMP participants. Differential miRNA expression and pathway enrichment analyses were conducted to characterize cluster-associated molecular features. Clinical characteristics and budesonide-related changes in lung function were compared across clusters, including analyses stratified by peripheral blood eosinophil counts.
resultsThree possible molecular clusters were identified, each with distinct miRNA expression patterns and enriched biological pathways. All clusters showed enrichment in IL-4/IL-13 signaling and PIP3/AKT pathways. Cluster 1 was characterized by Toll-like receptor-related signaling pathways, Cluster 2 by FOXO-mediated transcription pathways, and Cluster 3 by pathways associated with SCF-KIT signaling. Baseline demographic and clinical characteristics were largely similar across clusters. However, patterns of budesonide-related lung function change differed. Clusters 1 and 3 showed more favorable lung function profiles after budesonide treatment than Cluster 2. In Cluster 1, eosinophilic participants had a higher proportion of moderate asthma, whereas those without eosinophilia were more often classified as having mild asthma. In Cluster 3, eosinophilic participants had greater baseline airway hyperresponsiveness and lower baseline FEV
conclusionmiRNA profiling identified possible molecular asthma clusters with different clinical, physiologic, and treatment-related patterns.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.